164 related articles for article (PubMed ID: 15827204)
41. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
42. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
Barkholt L; Linde A; Falk KI
Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
[TBL] [Abstract][Full Text] [Related]
43. Cytotoxic effects of NF‑κB inhibitors in combination with anti‑herpes agents on Epstein‑Barr virus‑positive gastric carcinoma in vitro.
Ordonez P; Nandakumar A; Koriyama C; Yamomoto M; Akiba S
Mol Med Rep; 2016 Sep; 14(3):2359-67. PubMed ID: 27430429
[TBL] [Abstract][Full Text] [Related]
44. Epstein-Barr virus (EBV)-associated primary central nervous system lymphoma: is incidence of EBV expression associated with median survival time?
Utsuki S; Oka H; Miyajima Y; Kijima C; Yasui Y; Fujii K
Brain Tumor Pathol; 2011 Apr; 28(2):145-9. PubMed ID: 21327439
[TBL] [Abstract][Full Text] [Related]
45. Epstein-Barr virus-mediated protection against etoposide-induced apoptosis in BJA-B B cell lymphoma cells: role of Bcl-2 and caspase proteins.
Blood A; Edwards CJ; Ishii HH; Pat BK; Bryson G; Sculley TB; Gobe GC
Arch Virol; 2004 Feb; 149(2):289-302. PubMed ID: 14745596
[TBL] [Abstract][Full Text] [Related]
46. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
47. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
48. A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy.
Chung YL; Lee YH; Yen SH; Chi KH
Clin Cancer Res; 2000 Apr; 6(4):1452-8. PubMed ID: 10778977
[TBL] [Abstract][Full Text] [Related]
49. High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice.
Decaudin D; Marszak FB; Couturier J; Mathiot C; Martin A; Némati F; Lantz O; Santo Jd; Arnaud P; Bordier V; Vincent-Salomon A; Poupon MF
Anticancer Drugs; 2006 Jul; 17(6):685-95. PubMed ID: 16917214
[TBL] [Abstract][Full Text] [Related]
50. HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer.
Lifang Y; Min T; Midan A; Ya C
J Exp Clin Cancer Res; 2008 Sep; 27(1):42. PubMed ID: 18811956
[TBL] [Abstract][Full Text] [Related]
51. Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.
Kenney S
Trans Am Clin Climatol Assoc; 2006; 117():55-73; discussion 73-4. PubMed ID: 18528464
[TBL] [Abstract][Full Text] [Related]
52. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?
Savani BN; Pohlmann PR; Jagasia M; Chinratanalab W; Kassim A; Engelhardt B; Greer J; Schuening F; Goodman S
Blood; 2009 Jun; 113(24):6263-4. PubMed ID: 19520823
[No Abstract] [Full Text] [Related]
53. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.
Faller DV; Mentzer SJ; Perrine SP
Curr Opin Oncol; 2001 Sep; 13(5):360-7. PubMed ID: 11555713
[TBL] [Abstract][Full Text] [Related]
54. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.
Castillo JJ; Beltran BE; Miranda RN; Young KH; Chavez JC; Sotomayor EM
Am J Hematol; 2016 May; 91(5):529-37. PubMed ID: 27093913
[TBL] [Abstract][Full Text] [Related]
55. Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Jones RJ; Iempridee T; Wang X; Lee HC; Mertz JE; Kenney SC; Lin HC; Baladandayuthapani V; Dawson CW; Shah JJ; Weber DM; Orlowski RZ
Clin Cancer Res; 2016 Oct; 22(19):4901-4912. PubMed ID: 27297582
[TBL] [Abstract][Full Text] [Related]
56. Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphoma.
Park S; Noguera ME; Brière J; Feuillard J; Cayuela JM; Sigaux F; Brice P
Hematol J; 2002; 3(6):317-20. PubMed ID: 12522456
[TBL] [Abstract][Full Text] [Related]
57. Treatment of lympho-proliferative disease with rituximab.
Niedermeyer J; Hoffmeyer F; Hertenstein B; Hoeper MM; Fabel H
Lancet; 2000 Feb; 355(9202):499. PubMed ID: 10841158
[No Abstract] [Full Text] [Related]
58. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1.
Kim JH; Kim WS; Park C
Leuk Lymphoma; 2012 Aug; 53(8):1586-91. PubMed ID: 22268450
[TBL] [Abstract][Full Text] [Related]
59. Novel Therapeutics for Epstein⁻Barr Virus.
Andrei G; Trompet E; Snoeck R
Molecules; 2019 Mar; 24(5):. PubMed ID: 30871092
[TBL] [Abstract][Full Text] [Related]
60. Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells.
Hoover SE; Kawada J; Wilson W; Cohen JI
J Infect Dis; 2008 Aug; 198(3):318-23. PubMed ID: 18544038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
